Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
Bispecific (CD20×CD3)
Glofitamab
Columvi · Glofit
A 2:1 CD20×CD3 bispecific — obinutuzumab pretreatment tames the CRS that drives its renal risk.
ModerateT-cell-engaging bispecific · approved 2023
Diffuse large B-cell lymphomaLarge B-cell lymphoma
Signature kidney injury
Prerenal / Hemodynamic AKI
No direct tubular signal. AKI is case-level, downstream of CRS (~63% any-grade, grade >=3 in ~4% after obinutuzumab pretreatment and step-up dosing) and tumor lysis; renal incidence not separately quantified — emerging data.
Source: Dickinson et al., N Engl J Med 2022
Mechanism of kidney injury
Indirect. CRS-associated cytokine release lowers renal perfusion through hypotension and capillary leak (prerenal AKI), while rapid B-cell lysis can cause tumor lysis with urate/phosphate crystal tubular injury. The mandatory obinutuzumab pretreatment dose debulks the B-cell compartment so that the first glofitamab exposure provokes a smaller cytokine surge, and step-up dosing further reduces CRS severity.
Clinical presentation
Creatinine rise with CRS (fever, hypotension); tumor-lysis electrolyte derangements in bulky disease. Bland urinalysis is typical.
Onset
Early — concentrated around cycle 1 step-up dosing and the first full dose.
Reversibility
Reversible
Anticancer mechanism
CD20×CD3 T-cell-engaging bispecific in a 2:1 (bivalent CD20, monovalent CD3) configuration, given as fixed-duration therapy after a single obinutuzumab pretreatment dose to deplete circulating and bulky B cells. Approved for relapsed/refractory diffuse large B-cell lymphoma after two or more prior lines.
Management
Manage CRS with supportive care, tocilizumab and corticosteroids per grade; restore renal perfusion; correct tumor-lysis electrolytes; supportive AKI care including dialysis if severe.
Risk factors
- High/bulky tumor burden
- Rapidly proliferative disease
- Volume depletion
- Pre-existing CKD
Prevention
- Obinutuzumab pretreatment (B-cell debulking)
- Step-up priming doses
- CRS monitoring with early tocilizumab/steroids
- Tumor lysis prophylaxis (hydration, allopurinol/rasburicase)
Note · Renal data emerging; no established direct nephrotoxicity. Risk mediated by CRS and tumor lysis.
Clinical depth
Renal dose adjustment
No specific renal dose adjustment defined; IgG bispecific exposure is not expected to be renally dependent. No dedicated data in severe impairment/ESKD.
Dialyzability & ESKD dosing
Not dialyzable (large IgG, reticuloendothelial clearance). No supplemental dosing for HD/PD.
Differential diagnosis
Distinguish CRS prerenal AKI from tumor lysis AKI; the obinutuzumab pretreatment lowers (but does not abolish) the cytokine-driven hemodynamic insult. Drug-intrinsic tubular toxicity is not established.
Monitoring
- Creatinine and electrolytes (K, phosphate, uric acid, calcium) around the obinutuzumab dose and each step-up
- CRS vital signs/inflammatory markers during the priming cycle
- Tumor lysis labs in high-burden disease during initial dosing
Key trials & series
- NP30179 / Dickinson NEJM 2022 pivotal phase 2 (CRS 63%, grade >=3 in 4%)
Clinical pearls
- The obinutuzumab pre-dose is a deliberate CRS-mitigation step — it debulks B cells before the bispecific fully engages.
- Fixed-duration dosing means the renal-risk window is front-loaded around the step-up; later cycles rarely produce new CRS-driven AKI.
- Most AKI is hemodynamic and reverses with CRS control and volume repletion.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
Prerenal / Hemodynamic AKIElectrolyte Wasting
Beyond the kidney
Class-level context for the major non-renal toxicities of bispecific (cd20×cd3)s.
Immune / Infusion
CRS, infusion reactions, irAEs, anaphylaxis
- Cytokine release syndrome
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
- ICANS / neurotoxicity
Hematologic
Cytopenias, thrombosis, TMA
- Cytopenias, hypogammaglobulinemia
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkGlofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Dickinson MJ et al. · N Engl J Med 2022 · PMID 36507690Pivotal phase 2: CRS in 63% (grade >=3 in 4%) after obinutuzumab pretreatment. Basis for CRS-mediated renal risk.PMIDAcute Kidney Injury in Cancer Immunotherapy Recipients.Joseph A et al. · Cells 2022 · PMID 36552755Onconephrology review of AKI mechanisms with bispecific T-cell engagers (CRS, TLS, infiltration).PMIDCollapsing Focal Segmental Glomerulosclerosis and Acute Kidney Injury Associated With Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Case Report.Acharya R et al. · Kidney Med 2021 · PMID 34939018Collapsing glomerulopathy/AKI with CRS and a CD3 engager — the rare glomerular pattern.PMIDEmergencies in Hematology: Why, When and How I Treat?Duminuco A et al. · J Clin Med 2024 · PMID 39768494CRS and tumor lysis (AKI/electrolytes) as emergencies with bispecifics.PMIDTumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.Howard SC et al. · Ann Hematol 2016 · PMID 26758269TLS risk across novel hematologic agents.PMIDAnticancer Drug-Induced Acute Kidney Injury.Izzedine H et al. · Kidney Int Rep 2017 · PMID 29318217Onconephrology reference for prerenal/tumor-lysis AKI.
Related agents
Other agents sharing the same signature kidney injury.